Computational Design of Peptide Inhibitors Targeting the Hemagglutinin of Canine Influenza Virus

Introduction

Canine influenza virus (CIV) is an enveloped, negative-sense single-stranded RNA virus belonging to the family Orthomyxoviridae, genus Influenzavirus A. CIV causes acute respiratory disease in dogs, with clinical signs including cough, nasal discharge, fever, and in severe cases pneumonia. Two major subtypes, H3N8 and H3N2, have circulated in canine populations, with H3N2 now predominant in Asia and North America. The hemagglutinin (HA) glycoprotein on the viral envelope mediates receptor binding and membrane fusion, making it a primary target for antiviral intervention. Peptide inhibitors that block HA function represent a promising therapeutic strategy, as they can be designed with high specificity and low immunogenicity.

Computational design of such inhibitors leverages structural bioinformatics, molecular docking, molecular dynamics (MD) simulations, and in silico mutagenesis to identify and optimize peptide sequences that bind to conserved regions of HA and disrupt its function. This article describes an integrated computational pipeline for the rational design of peptide inhibitors targeting CIV HA, drawing on established principles from influenza A virus entry inhibitor research [1]. The workflow is applicable to both H3N8 and H3N2 CIV subtypes and can be extended to other influenza A viruses with zoonotic potential.

Relevance of CIV in Veterinary Medicine and Cross-Species Transmission

CIV emerged as a significant canine pathogen after the introduction of equine H3N8 in the early 2000s and later the direct transmission of avian H3N2 to dogs. The virus continues to circulate in kennels, shelters, and veterinary clinics, causing outbreaks with substantial morbidity. Moreover, CIV has demonstrated the capacity for reverse zoonosis, with documented transmission from dogs to cats and ferrets. The potential for CIV to reassort with other influenza A viruses, including avian and swine strains, raises concerns about the emergence of novel pandemic strains. Effective antiviral agents, including peptide-based entry inhibitors, could serve as critical tools for outbreak control and pandemic preparedness.

In this context, targeting the hemagglutinin receptor binding site (RBS) and the stem region, which is highly conserved across influenza A subtypes, offers a route to broad-spectrum inhibition. Computational methods accelerate the identification of lead peptide sequences by reducing the need for exhaustive experimental screening.

Computational Workflow Overview

The computational design pipeline consists of four major stages: (1) receptor binding domain analysis and structural preparation, (2) molecular docking of peptide libraries to HA, (3) molecular dynamics simulations to evaluate binding stability and conformational dynamics, and (4) in silico mutagenesis to optimize peptide binding affinity and specificity. The workflow is summarized in Figure 1.

flowchart TD
    A[HA Structure Selection], > B[Receptor Binding Domain Analysis]
    B, > C[Peptide Library Generation]
    C, > D[Molecular Docking]
    D, > E[Binding Pose Clustering & Scoring]
    E, > F[MD Simulations of Top Candidates]
    F, > G[Binding Free Energy Calculation]
    G, > H[In Silico Alanine Scanning]
    H, > I[Lead Optimization]
    I, > J[Experimental Validation]

Figure 1. Computational workflow for the design of peptide inhibitors targeting CIV hemagglutinin.

Receptor Binding Domain Analysis

The first step requires a high-resolution three-dimensional structure of CIV HA. For H3N2 CIV, cryo-electron microscopy or X-ray crystallography structures of the HA trimer are available in the Protein Data Bank (PDB). For subtypes without solved structures, homology modeling using templates from related influenza A H3 HAs can generate reliable conformations. The receptor binding site (RBS) is located at the membrane-distal globular head of each HA monomer and comprises three key elements: the 130-loop, the 190-helix, and the 220-loop. The conserved stem region contains the fusion peptide and is targeted by neutralizing antibodies.

Sequence alignment of CIV HA with human, avian, and equine HA sequences reveals conserved residues critical for receptor binding, such as Tyr98, Trp153, His183, and Tyr195 (H3 numbering). These residues form the sialic acid binding pocket and are prime targets for competitive peptide inhibitors. The solvent-accessible surface area of the RBS and the electrostatic potential are computed using tools such as APBS and FreeSASA. The identified pocket volume and hydrophobicity guide the selection of peptide length and composition.

For example, peptides of 10 to 20 amino acids are typically designed to mimic the sialic acid moiety or to bind to the conserved stem groove. Linear and cyclic peptides can be modeled, with cyclic variants often conferring greater conformational rigidity and improved binding affinity.

Molecular Docking Simulations

Molecular docking predicts the preferred orientation and conformation of a peptide ligand within the HA binding site. AutoDock Vina, Glide (Schrödinger), and HADDOCK are commonly used programs for protein-peptide docking. The docking protocol involves preparing the HA receptor (adding hydrogens, assigning charges) and constructing a peptide library. The library can be generated combinatorially or based on known sequences from previous studies of influenza A HA inhibitors [1]. For CIV HA, the grid center is positioned at the centroid of the RBS or the stem pocket, with a grid box large enough to accommodate peptides up to 20 residues.

Scoring functions rank docked poses by estimating binding free energy. Multiple scoring functions (e.g., AutoDock Vina scoring, MM-GBSA) can be combined to improve ranking accuracy. The top-ranked poses are clustered by root-mean-square deviation (RMSD) of atomic positions, and representative poses from the most populated clusters are selected for further analysis. A typical docking study may screen 10,000 peptide candidates and yield 50 to 100 high-scoring leads.

Table 1 provides an example summary of docking results for a set of hypothetical peptide inhibitors against CIV H3N2 HA.

Table 1. Example docking results for peptide candidates against CIV HA. Docking scores indicate predicted binding affinity.

Molecular Dynamics Simulations for Stability Assessment

Molecular dynamics simulations provide insight into the dynamic behavior of peptide-HA complexes under physiological conditions. Using software packages such as GROMACS, AMBER, or NAMD, the complex is solvated in a water box with appropriate ionic concentration, energy minimized, and equilibrated. Production runs of 50 to 200 nanoseconds are performed with a 2 fs timestep, using force fields such as CHARMM36 or AMBER ff14SB for the protein and peptide.

Analysis of MD trajectories focuses on the root-mean-square fluctuation (RMSF) of peptide residues, the number of stable intermolecular hydrogen bonds, and the binding free energy calculated via the Molecular Mechanics Generalized Born Surface Area (MM-GBSA) or Poisson-Boltzmann Surface Area (MM-PBSA) method. A successful inhibitor should maintain contact with key HA residues throughout the simulation, with low peptide RMSF and favorable binding free energy (e.g., less than -20 kcal/mol).

MD simulations can also reveal induced-fit conformational changes in HA that may affect inhibitor binding. For CIV HA, the stem region is relatively rigid, whereas the RBS loops can exhibit flexibility. Peptides that accommodate this flexibility without losing critical interactions are prioritized.

In Silico Mutagenesis and Lead Optimization

In silico mutagenesis, including alanine scanning, systematically replaces each amino acid in the peptide with alanine to evaluate its contribution to binding affinity. Computational alanine scanning using MM-GBSA or FoldX identifies "hotspot" residues: mutations that significantly reduce binding (increase free energy by more than 1.0 kcal/mol) indicate critical interactions. Conversely, mutations that improve binding suggest positions for optimization.

For CIV HA-targeted peptides, optimization may involve substituting natural amino acids with non-natural analogs to enhance proteolytic stability, or cyclization to lock the peptide in the active conformation. Computational tools such as Rosetta and PyRosetta allow for design of cyclic peptides and estimation of their binding energies.

The final lead peptides are then synthesized and tested in vitro for hemagglutination inhibition, cell-based entry assays, and neutralization of live CIV. The computational pipeline thus reduces the number of candidates to a manageable set for experimental validation.

Visualization Using the 3D Protein Viewer

A web-based 3D protein viewer enables interactive visualization of CIV HA structure and predicted peptide binding modes. Users can load a PDB file of the HA trimer (e.g., from the Protein Data Bank or a homology model) and overlay docked peptide poses. The viewer displays molecular surfaces, electrostatic potentials, and hydrogen bond networks. Key residues in the receptor binding site can be highlighted, and peptide interactions can be measured (distances, angles). This tool is invaluable for verifying docking results and for communicating structural insights to computational and experimental collaborators.

To explore the HA structure, visit the related article on Canine Influenza H3N2 for sequence information, or use the Structure-Based Drug Design in Bioinformatics resource for guidance on working with molecular viewers.

Cross-Linking to Related Resources

The computational approach described here is part of a broader field of antiviral peptide design. For additional context, readers are referred to the following articles:

• Computational Design of Antiviral Peptides Targeting Viral Envelope Proteins
• In Silico Design of Peptide-Based Viral Entry Inhibitors Targeting Class I Fusion Proteins
• Structural and Computational Insights into Henipavirus Receptor Binding
• Computational Analysis of Avian Influenza Hemagglutinin Receptor Binding Specificity
• Structure-Guided Design of Broad-Spectrum Viral Fusion Inhibitors
• Structural Dynamics of Avian Influenza Hemagglutinin: Molecular Modeling and Receptor Binding Predictions
• Multiplex RT-qPCR for Differential Diagnosis of Canine Respiratory Pathogens
• Influenza A Virus in Cats

These resources offer complementary methodologies and host-range perspectives.

Conclusion

Computational design of peptide inhibitors targeting CIV hemagglutinin provides a rational, efficient route to novel antiviral agents. By integrating receptor binding domain analysis, molecular docking, molecular dynamics simulations, and in silico mutagenesis, researchers can identify and optimize peptide leads with high specificity for conserved HA regions. The pipeline is adaptable to other influenza A subtypes and can be extended to address emerging strains with zoonotic potential. Continued development of computational tools and structural databases will further accelerate the discovery of peptide-based therapeutics for canine influenza and other viral diseases.

References

[1] Lin D, Luo Y, Yang G, et al. Potent influenza A virus entry inhibitors targeting a conserved region of hemagglutinin. Biochem Pharmacol. 2017. URL: https://pubmed.ncbi.nlm.nih.gov/28774731/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.